Pay in 4 interest-free payments of $5.86 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Karagiannis T, Avgerinos I, Liakos A et al (2022) Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
The Study at a Glance Who was studied: 132 children and adolescents aged 1017 with type 2 diabetes Duration: 52 weeks (with the primary endpoint measured at week 26) Design: Randomized, double-blind, placebo-controlled Drug: Oral semaglutide at once-daily doses of 3 mg, 7 mg, or 14 mg Background therapy: Participants continued on metformin, basal insulin, or both The Results The trial met its primary endpoint
Tirzepatide has the potential to be the first pharmaceutical treatment for the underlying disease. Jeff Emmick Eli Lilly is now doing just that
Aguiar-Oliveira, M
US$ 27.08
US$ 29.67
US$ 23.12
US$ 23.50
US$ 26.93
US$ 25.72
